Company
SI-BONE
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
26
510(k), De Novo and PMA
Device trials
9
As lead sponsor, any status
Adverse event reports
1
Received Nov 1, 2025 to Nov 19, 2026
Recall records
1
One per recalled product
SI-BONE is on our public-company list (ticker SIBN). Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
SIBN
Nasdaq · SI-BONE, Inc.
Public float
$800M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$201M
Fiscal year ending Dec 31, 2025
Net income
-$18.9M
Fiscal year ending Dec 31, 2025
R&D spending
$17.4M
Fiscal year ending Dec 31, 2025
Cash
$35.3M
As of Sep 30, 2026
Long-term debt
$35.7M
As of Sep 30, 2026
Shares outstanding
45.1M
As of Oct 28, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2024 | – | – | $36.0M | – |
| 2023 | – | $83.7M | $36.0M | – |
| 2021 | – | – | $35.0M | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
Company details
From the company's latest Form D.
- Legal name
- SI-BONE, Inc.
- Headquarters
- San Jose, California
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other
- SEC filer
- CIK 1459839 ↗
Executives, directors and promoters
As listed on the latest Form D.
10 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 26 since 2015.
K262067 · Decided Sep 23, 2026 · 93 days after receipt
Device type: Thoracolumbosacral Pedicle Screw System (NKB) · Orthopedic Surgery
K253488 · Decided Feb 11, 2026 · 110 days after receipt
Device type: Sacroiliac Joint Fixation (OUR) · Orthopedic Surgery
K253094 · Decided Oct 9, 2025 · 16 days after receipt
Device type: Sacroiliac Joint Fixation (OUR) · Orthopedic Surgery
23 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring FracturesRecruiting
NCT07530497 · 120 participants (planned) · Start Aug 24, 2026 · Primary completion Feb 2028
Device: iFuse TORQ TNT Implant System · For: Fracture; Pelvic; Insufficiency Fractures; Fragility Fracture and 3 more
Sites: Los Angeles, California; Edina, Minnesota; Rochester, Minnesota · 4 sites in all
- Posterior-Inferior Intra-articular Cortical Piercing Titanium Implant for Sacroiliac Joint Fusion: Evaluation of Safety and Effectiveness OutcomesNot yet recruiting
NCT07565545 · 120 participants (planned) · Start Dec 2026 · Primary completion Jun 2028
Device: iFuse INTRA Ti Implant System · For: Sacro Iliac Joint Pain; Sacro-iliac Joints; Sacroiliac Disorder and 3 more
- iFuse TORQ for the Treatment of Sacroiliac Joint DysfunctionActive, not recruiting
NCT05870488 · 110 participants (planned) · Start May 23, 2023 · Primary completion Apr 23, 2025
Device: Use of iFuse TORQ · For: Sacroiliac Joint Dysfunction; Sacroiliac; Fusion; Sacroiliac Disorder and 1 more
Sites: Napa, California; Santa Monica, California; Shelbyville, Indiana · 14 sites in all
6 more trials with a free account
Reports received
1
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
0.0% of reports
Injury reports
1
100% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 1 | 0 | 0 |
| May 24 | 0 | 1 | 0 | 0 |
| Jun 24 | 0 | 1 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 1 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 1 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 1 | 0 | 0 |
| Apr 25 | 0 | 1 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 1 | 0 | 0 |
| Jul 25 | 0 | 1 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 1 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- iFuse TORQ Implant System Model/Catalog Number: 10055T(10x55mm), 10060T(10x60mm), 10065T(10x65mm), 10080T(10x55mm), 11580T(11.5x80mm)Open, Classified
Z-0146-2027 · Started Aug 21, 2026 · Posted by FDA Oct 9, 2026
Reason given: The pelvic fixation screws failed to meet acceptance criteria for tube packaging seal integrity testing; therefore, sterility assurance cannot be ensured.
Cause as FDA categorized it: Packaging · Device type: Sacroiliac Joint Fixation (OUR)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.